Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results

被引：0

作者：

Benn, P. ^{[1
]}

Quercia, R. ^{[2
]}

Hudson, K. ^{[3
]}

Wang, Y. ^{[4
]}

Chounta, V. ^{[5
]}

Talarico, C. ^{[6
]}

Ford, S. ^{[7
]}

Cutrell, A. ^{[8
]}

Margolis, D. ^{[9
]}

Van Solingen-Ristea, R. ^{[10
]}

Vanveggel, S. ^{[10
]}

Van Eygen, V. ^{[10
]}

Polli, J. ^{[11
]}

de Ruiter, A. ^{[11
]}

Smith, K. ^{[12
]}

Spreen, W. ^{[9
]}

机构：

[1] ViiV Healthcare, Clin Dev, Brentford, England

[2] ViiV Healthcare, Clin Virol, Brentford, England

[3] ViiV Healthcare, Clin Dev, Res Triangle Pk, NC USA

[4] GlaxoSmithKline, Stat, R&D, Collegeville, PA USA

[5] ViiV Healthcare, Global Hlth Outcomes, Brentford, England

[6] ViiV Healthcare, Translat Med Res, Res Triangle Pk, NC USA

[7] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Res Triangle Pk, NC USA

[8] ViiV Healthcare, Stat, R&D, Res Triangle Pk, NC USA

[9] ViiV Healthcare, Clin Dev, R&D, Res Triangle Pk, NC USA

[10] Janssen Res & Dev, Clin R&D, Beerse, Belgium

[11] ViiV Healthcare, Global Med Sci, Res Triangle Pk, NC USA

[12] ViiV Healthcare, R&D, Res Triangle Pk, NC USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P017

引用

页码：28 / 29

页数：2

共 50 条

[21] Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
Miranda Murray
Antonio Antela
Anthony Mills
Jenny Huang
Hans Jäger
Enrique Bernal
Johan Lombaard
Harold Katner
Sharon Walmsley
Marie-Aude Khuong-Josses
Krischan Hudson
David Dorey
Sandy Griffith
William Spreen
Simon Vanveggel
Mark Shaefer
David Margolis
Vasiliki Chounta
AIDS and Behavior, 2020, 24 : 3533 - 3544
[22] Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results
D'Amico, R.
Orkin, C.
Bernal Morell, E.
Tan, D.
Katner, H.
Singh, Y.
Stellbrink, H.
Belonosova, E.
DeMoor, R.
Griffith, S.
Thiagarajah, S.
Van Solingen-Ristea, R.
Crauwels, H.
Ford, S.
Patel, P.
Cutrell, A.
Smith, K.
Vandermeulen, K.
Margolis, D.
St Clair, M.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 10 - 12
[23] The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment
Alberton, Francesca
Nozza, Silvia
Raccagni, Angelo Roberto
Galli, Laura
Spagnuolo, Vincenzo
Bossolasco, Simona
Cernuschi, Massimo
Canetti, Diana
Hasson, Hamid
Castagna, Antonella
Gianotti, Nicola
JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
[24] Long-acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 (HIV-1) Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-label, Phase 3b, Noninferiority Study
Overton, Edgar T.
Richmond, Gary
Rizzardini, Giuliano
Thalme, Anders
Girard, Pierre-Marie
Wong, Alexander
Porteiro, Norma
Swindells, Susan
Reynes, Jacques
Noe, Sebastian
Harrington, Conn
Espanol, Carlos Martin
Acuipil, Carolina
Aksar, Asma
Wang, Yuanyuan
Ford, Susan L.
Crauwels, Herta
van Eygen, Veerle
Van Solingen-Ristea, Rodica
Latham, Christine L.
Thiagarajah, Shanker
D'Amico, Ronald
Smith, Kimberly Y.
Vandermeulen, Kati
Spreen, William R.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) : 1646 - 1654
[25] Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China
Li, Mengqing
Guan, Hongjing
Zhong, Mingli
Di, Xiaoyun
Yu, Nawei
Chen, Chen
Cai, Rentian
Wei, Hongxia
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2025, 41 (02) : 107 - 112
[26] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in patients with suppressed HIV-1
Chounta, V.
Snedecor, S.
Van de Velde, N.
HIV MEDICINE, 2020, 21 : 28 - 29
[27] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients
Chounta, V.
Snedecor, S.
Wu, S.
Van de Velde, N.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 23 - 24
[28] A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies
Margolis, D.
Schapiro, J.
Perno, C.
Kuritzkes, D.
Quercia, R.
Patel, P.
Polli, J.
Cutrell, A.
Dorey, D.
Wang, Y.
Wu, S.
van Eygen, V.
Crauwels, H.
Ford, S.
Baker, M.
Talarico, C.
St Clair, M.
Jeffrey, J.
White, C.
Vanveggel, S.
Van Solingen-Ristea, R.
Vandermeulen, K.
Spreen, W.
van Lunzen, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 15 - 16
[29] A combination of viral and participant factors influence virological outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M Phase 3 studies
Patel, Parul
Schapiro, Jonathan
Perno, Carlo
Kuritzkes, Daniel
Cutrell, Amy
Dorey, David
Wang, Yongwei
Van Eygen, Veerle
Crauwels, Herta
Ford, Susan
Talarico, Christine
St Clair, Marty
Jeffrey, Jerry
Vandermeulen, Kati
Spreen, William
Van Lunzen, Jan
HIV MEDICINE, 2021, 22 : 26 - 27
[30] Drug-related neuropsychiatric adverse events across phase III/IIIb studies of long-acting cabotegravir plus rilpivirine through week 48
Elliot, E.
Teichner, P.
Dakhia, S.
Polli, J.
Patel, P.
Garside, L.
Byrapuneni, S.
Thiagarajah, S.
D'Amico, R.
Van Solingen-Ristea, R.
Birmingham, E.
Baugh, B.
van Wyk, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 157 - 158

← 1 2 3 4 5 →